Dextroamphetamine

摘要 桥接（bridging）指在新药开发中，利用现有已知药物（或活性代谢物）的毒性数据来支持申请，而非重新做完整的非临床试验。FDA近年来明确允许在新药暴露主体已知且与已有数据库完全一致的情况下采用桥接策略。Vyvanse（赖右苯丙胺）的活性成分是右旋安非他明（d-amphetamine），其本身为无活性的前药：体内经水解几乎完全转化为安非他明。因此FDA接受将Vyvanse的长期毒性评估建立在安非他明已有数据之上，而无需重新做两年致癌研究。本文结合FDA审批资料（NDA审评报告、标签等），介绍桥接概念及Vyvanse案例：分析其代谢路线和非临床证据，列举FDA在此类桥接评估中的关键要点，并讨论监管伦理考虑和申报实践建议。1. 桥接概念：何时适用？ 桥接（Exposure/Riskbridging）是指：当新药的主要暴露物质与现有药物（或代谢物）相同或可预测时，用已有数据代替部分新试验。核心条件是： 相同活性成分：新药和已有药物最终作用机制一致。如Vyvanse代谢产物为右旋安非他明，与其他安非他明类药物活性相同。 暴露主体一致：新药体内原形含量低，几乎不产生新毒性；主要风险来源于已知活性代谢物。FDA允许把“同样危险主题”的历史数据用于新药评估。Vyvanse服用后原药浓度极低，几乎全部以安非他明形式存在。 现有数据库丰富：已有药物（或代谢物）在相同终点上有完整资料，包括致癌、生殖毒性等。安非他明被NTP（美国国家毒理学计划）做过两年致癌试验，无致癌作用。 科学原理支撑：如FDA草案指南（GASK）指出，在科学共识基础上，可引用已知知识替代部分实验。 在满足上述条件时，FDA认为重复大量动物研究浪费资源且无增益，可采纳桥接。反之，如新药代谢未知、活性物质不同、现有数据不足或安全边界有疑虑，桥接则不适用（例如新分子结构、代谢途径差异大时）。2. Vyvanse案例详解：为何适用桥接 代谢路径：赖右苯丙胺（Lisdexamfetamine，NRP-104）口服后在红细胞中经酶解裂解，释放右旋安非他明（d-amphetamine）和L-赖氨酸。未代谢的赖右苯丙胺极少，且其对中枢无直接作用。临床与体内试验证明：注射原药物（或给予原药）不产生活动兴奋，需要先转换为安非他明才能发挥效应。换言之，赖右苯丙胺自身基本无效，只有代谢后的安非他明才活跃。 药理学证据：研究表明，赖右苯丙胺对安非他明受体几乎无亲和力，体外实验中对DA/NE转运体无结合活性，动物中也无兴奋剂样急效反应。其生理作用与安非他明吻合：在大鼠、狗等毒理学研究中，高剂量赖右苯丙胺引起的中枢兴奋、活动增加、重复刻板行为，与安非他明所致极为相似。FDA审评指出：在安全药理学和毒理学研究中观察到的所有效应都与安非他明一致。因此不存在赖右苯丙胺特有的新型毒性信号。 药代动力学：多项PK研究表明，给药赖右苯丙胺后体内产生的安非他明曲线更平缓：其血药峰值（Cmax）比等量安非他明要低3～4倍且出现时间更晚，而总暴露（AUC）在剂量稍高时可与安非他明匹配。例如，25mg赖右苯丙胺产生的安非他明AUC与10mg安非他明相当；50mg赖右苯丙胺相当于20mg安非他明。这意味着在临床推荐剂量下，两者的安非他明暴露水平相近。FDA审评利用这些数据确认：赖右苯丙胺只是一种缓释前药，使得体内安非他明的吸收更平稳，降低急性中毒风险。 毒理学/遗传毒理学：如上所述，赖右苯丙胺在毒理研究中未见新的目标器官或机理。所有观察到的毒性（皮肤病变、行为异常、体重下降等）均为安非他明兴奋剂作用的典型表现。致突变性试验中，赖右苯丙胺在Ames、小鼠淋巴瘤和小鼠骨髓微核等实验均为阴性；安非他明本身亦未表现出明确遗传毒性（部分报告为阴性，偶有个别不确定结果）。因此不存在赖右苯丙胺携带新遗传风险的证据。 综上，Vyvanse的非临床资料清楚显示：赖右苯丙胺自身几乎不活跃，其药理毒性完全通过安非他明发挥（活性完全“桥接”到安非他明身上）。FDA审评认为，可安全地使用安非他明相关数据来预测和保障Vyvanse的安全性，无需重复2年致癌实验。3. FDA评估要点清单 在批准Vyvanse时，FDA主要依赖以下证据和原则判断桥接合理性： 暴露比较：对比双盲PK数据，确认服药后安非他明在体内的浓度-时间曲线与直接用药相似。Vyvanse研究表明：相同剂量级别，安非他明暴露量相仿，赖右苯丙胺血药峰值极低。只要保证安非他明达到既有安全剂量范围内，即可桥接已知数据。 代谢物比例：赖右苯丙胺经体内几乎100%转化为安非他明。FDA要求证明“无活性原药在体内残留极少”，本案满足这一条件。数据表明即使高剂量，原型药物并未显著积累，也无新代谢物出现。 毒性谱相似性：Vyvanse的所有毒性终点都与安非他明一致，无异常器官或症状。FDA检查包括心血管、中枢等安全药理学研究，结果与安非他明类药物相似。如需桥接，必须无新的毒效学风险，Vyvanse正符合这一点。 PK参数对比（Cmax/AUC）：FDA强调直接对比关键PK参数。Vyvanse在等效暴露条件下产生的安非他明Cmax明显低于纯药，但AUC可调节匹配。这一点表明安非他明峰值低、持续暴露存在，有利于安全。监管者认为只要总暴露(AUC)相当且峰值更低，不会遗漏毒性风险。 对照组价值：FDA审评中通常要求把安非他明作为参照组来“复核”赖右苯丙胺的非临床结果。Vyvanse的某些毒理研究中（如28天重复给药）额外设置了安非他明对照组，结果显示两者效应高度相似。这种直接对照增强了桥接论证可信度。FDA认为，将已知化合物纳入研究，可明确对比安全性。 致癌性数据桥接：Vyvanse虽未做自己的人或动物长期致癌实验，但FDA接受引用安非他明的NTP研究结果。理由是：长期暴露主要是安非他明，不是前药；已有的安非他明致癌性研究（NTP1991）显示在大鼠小鼠中无致瘤性；FDA还查阅了安非他明的临床使用史和人群数据，均未发现明确致癌信号。因此在符合安全边际的前提下，长达2年致癌试验被豁免。4. 桥接的监管 何时不可桥接：如果新药或其代谢途径中有未知风险，就不能桥接。例如： 新分子或未知代谢：若新药非前药或活性代谢物未知，不适用桥接。 多成分组合药物：不同组分间交互可能产生新风险。 变更给药途径/剂型：若给药方式改变可能改变吸收分布，需评估原型药在体内的差异。 对照缺失：若无法进行对照研究（如某些急性试验），FDA可能要求做新的测试。 数据缺口风险：桥接依赖现有知识，但也可能遗漏新发现，如：多年前未评估的罕见肿瘤类型，或仅在高剂量下才出现的亚慢性效应。因此，申请者需要做充分的安全监测和后续研究承诺。FDA在批准时通常会要求风险管理计划（Risk Management Plan），以确保新药上市后继续收集长期安全信息。伦理上，桥接可减少不必要的动物实验，尊重“3R原则”（减量、细化、替代），是符合科学和伦理的做法，但前提是证据链可靠。5. 药企实践建议 设计非临床研究时注意对比测试：在关键毒理和PK研究中，可设计相同剂量的活性物或参比药对照组（如安非他明组），为桥接提供直接依据。并同步测定前药和代谢物浓度。 充分准备数据包证明暴露相似：在申报资料中，应详细列出赖右苯丙胺与安非他明的PK参数对比（Cmax、Tmax、AUC），强调代谢率和体内活性物质一致性。如本案中，25mg前药≈10mg安非他明的AUC比值，就可以清楚说明暴露可桥接。 构建科学论证结构：申报文档中务必专门开章论述桥接逻辑，包括：代谢途径图、暴露对比表、已知数据库摘要（NTP报告、上市药物说明书等），并引用指南（如FDAGASK草案）支持思路。比如可以列出对照表或流程图：Lisdexamfetamine→(水解)→d-Amphetamine→已知毒理数据库，用数据和文献链接说明每一步合理性。 关注监管指引和沟通：虽然FDA目前无专门“桥接指导原则”，但可以参考FDA/EMA关于无新风险的非临床指导（如ICH M3、ICH S6）和FDA提倡的“公认科学知识”草案。在研发早期与监管部门沟通桥接计划，获取一致意见，能提高申报成功率。6. 结论 Vyvanse案例说明：FDA认可基于活性代谢物一致性的风险桥接。当药物的活性成分与历史药物相同且暴露可比，则新药可引用已有的非临床安全数据，省去冗余实验。这一策略既节约资源，又符合现代监管科学精神，但前提是必须有清晰科学逻辑和充分证据链支持。本案例的经验启示研发者：提前规划好PK/PD和毒理对照研究，在申报资料中突出暴露对比和现有数据库，向审评者证明“无新风险”。 写作/申报模板提示： 突出对比：用表格、流程图等方式清晰对比“前药→代谢物”与参考药物的暴露和效应。 强调已有数据：在申报中引述NTP报告和上市说明书等原始资料，证明代谢物数据库的适用性。 清晰逻辑链：每个结论都对应出处和数据支撑，如代谢比例、Cmax/AUC比值和毒性相似性，形成一条“暴露等同→风险等同”的论证链。 申报资料-模块4相关 【非临床、非临床】工艺未定、稳定性不全，非临床试验怎么做才不“翻车”？ 4.2 试验报告 4.2.1 药理学 4.2.1.1 主要药效学  案例分享 4.2.1.3 安全药理学申报（适用于单克隆抗体）示例解析 4.2.1.1 主要药效学：CDE审评10大致命问题1 4.2.1.1 主要药效学：CDE审评10大致命问题2 GLP不是做毒理——它真正要证明的，是你“样品没有问题” IND最容易被忽略的一道坎：毒理物种选错，数据全部失效 4.2.1.2 次要药效学（Secondary Pharmacodynamics）申报示例 为什么很多非临床数据，最后无法外推到人体？ 4.2.1.3 安全药理学：为什么很多药，根本死不到III期？真正的问题不在毒性，而在人体风险不可预测 CTD Module 4 非临床模块IND 阶段 vs NDA/BLA 阶段完成内容总览 一个未知杂质，为什么差点毁掉整个项目？——杂质研究，才是 CMC 与毒理真正交汇的核心节点 从逻辑的角度，真正理解 4.2.1.1 主要药效学为什么真正的主要药效学，不是在“证明有效”，而是在回答“这个药为什么能进入人体” 4.2.3.2 重复给药毒性（Repeat-Dose Toxicity）示例解析 为什么生物药时代，毒理学从“预测工具”变成了“机制验证工具”？ PD-1如何重构毒理学：从NOAEL到免疫系统状态模型 为什么“靶点一致”已经不再等于“药物一致”？ PK剂量与毒理剂量为什么必然“重叠”：非临床剂量体系的真实约束逻辑 为什么重复给药毒性研究正在告别MTD？——从剂量驱动到暴露驱动的监管转变 药效平台之后，我们到底还在探索什么？ 药效平台之后，我们到底还在探索什么？ 为什么说明书上的推荐剂量，并不一定是你的剂量？ Ka、CL、Vd都可能预测错，为什么IND依然能获批？ IND阶段ADME那些事：哪些未知可以接受，哪些未知会卡住项目？  —— 基于案例的监管思考 《50倍暴露以后，FDA到底还想看什么？》——安全边界（Exposure Margin）与毒性边界（Toxicity Boundary）的监管平衡 一个抗体从0到BLA的完整推演系列 《为什么90%的抗体项目，死在IND之前？不是科学问题，是CMC系统性失败》 《你以为POC成功了？其实抗体项目在这一刻已经埋雷》 制药竞争的下半场：从药效比拼到质量理解——一份不会写进申报资料，但必须被看见的行业现实 一致性评价的悖论：我们是在防风险，还是在锁进步？ 抗体研发最大的误区：你以为在做“更好的分子”，其实是在控制“分布” 目的基因序列：IND阶段如何从基因设计评估产品安全性 细胞库鉴定与产品可信性：CMC审评中的起点逻辑与证据边界 【工艺开发】工艺最终需要具备可验证性 【工艺开发】参数空间探索（CPP） 【工艺开发】FMEA的应用示例 【工艺开发】从“独立风险评估项目”看ICH Q9与PDA TR60：真正需要做的，不超过这几类 【工艺开发】QTPP → CQA → CPP看似标准路径，为什么项目卡死在“没有逻辑”的那一步？ 【工艺开发】一张图看懂：Characterized Range ≠ Design Space，企业会卡在这里 【工艺开发】CCD中的中心点：它不是工艺中间，而是模型升级的枢纽 【工艺开发】文献案例分享：工艺表征（Process Characterization）至设计空间的QbD实施 付费课程专栏 付费课程专栏 第一期 【工艺开发】用JMP构建基于概率约束的Design Space（QbD实战流程） 《为什么很多IND项目，死在CMC“不可控”——审评机构真正关注的10大隐性死亡点》 CTD 4.2.2.1 分析方法和验证报告模板研究与示范稿

Woburn, MA — April 6, 2026 — Azurity Pharmaceuticals, Inc. announced that ARYNTATM (lisdexamfetamine dimesylate) Oral Solution is now available in the United States for treating ADHD in adults and pediatric patients 6 years and older. Arynta, a ready-to-use lisdexamfetamine oral solution that may be stored at room temperature between 68°F to 77°F (20°C to 25°C),1 received FDA approval in June 2025. “Azurity Pharmaceuticals is proud to offer Arynta as an option for patients who need or prefer an oral liquid and are seeking flexibility in their treatment options,” said Ronald Scarboro, CEO of Azurity Pharmaceuticals. In pivotal Phase 3 clinical trials that evaluated the efficacy and safety of lisdexamfetamine across pediatric and adult patient populations, lisdexamfetamine demonstrated statistically significant efficacy for the core symptoms of hyperactive-impulsive and inattention in ADHD.1 As a prodrug of amphetamine, Arynta delivers reliable symptom control for up to 13 hours in children and up to 14 hours in adults, and its safety and tolerability profile is similar to that of other stimulant medication.1-5 Please read the full Prescribing Information, including Boxed Warning, and additional safety information at www.arynta.com. Azurity Pharmaceuticals is committed to serving overlooked patients, including those who have difficulty swallowing capsules or prefer a liquid form. It is reported that approximately 70% of children and about 30% of adolescents refuse or have difficulty swallowing tablets or capsules.6 Certain patient populations are more impacted than others. For example, about 40% of children with autism also have ADHD and many children with autism struggle with food texture hypersensitivity, which may make taking medication in capsule and sprinkle form a challenge.7-10 Arynta helps to address this need as part of Azurity’s innovative dose-form solutions. IMPORTANT SAFETY INFORMATION ARYNTATM (lisdexamfetamine dimesylate) Oral Solution, CII ARYNTA is a central nervous system (CNS) stimulant indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older. Moderate to severe binge eating disorder (BED) in adults. Limitations of Use: Pediatric patients with ADHD younger than 6 years of age experienced more long-term weight loss than patients 6 years and older. ARYNTA is not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of ARYNTA for the treatment of obesity have not been established. WARNING: ABUSE, MISUSE, AND ADDICTION ARYNTA has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including ARYNTA, can result in overdose and death [see Overdosage (10)], and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Before prescribing ARYNTA, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout ARYNTA treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction [see Warnings and Precautions (5.1), Drug Abuse and Dependence (9.2)]. ADDITIONAL IMPORTANT SAFETY INFORMATION Do not take ARYNTA if you or your child are: Allergic to amphetamine products or any of the ingredients in ARYNTA. Taking, or have stopped taking in the last 14 days, a medicine called Monoamine Oxidase Inhibitor (MAOI). Being treated with the antibiotic linezolid or intravenous methylene blue. What are the possible side effects of ARYNTA? ARYNTA may cause serious side effects, including: Abuse, misuse, and addiction: ARYNTA has a high chance for abuse and misuse and may lead to substance use problems, including addiction. Misuse and abuse of ARYNTA, other amphetamine containing medicines, and methylphenidate containing medicines, can lead to overdose and death. The risk of overdose and death is increased with higher doses of ARYNTA or when it is used in ways that are not approved, such as snorting or injection. Your healthcare provider should check you or your child’s risk for abuse, misuse, and addiction before starting treatment with ARYNTA and will monitor you or your child during treatment. ARYNTA may lead to physical dependence after prolonged use, even if taken as directed by your healthcare provider. Tell your healthcare provider if you or your child have ever abused or been dependent on alcohol, prescription medicines, or street drugs. Risks for people with serious heart disease: Sudden death has happened in people who have heart defects or other serious heart disease. Your provider should check you or your child carefully for heart problems before starting treatment with ARYNTA. Tell your healthcare provider if you or your child have any heart problems, heart disease, or heart defects. Increased blood pressure and heart rate: Your healthcare provider should check you or your child’s blood pressure and heart rate regularly during treatment with ARYNTA. Mental (psychiatric) problems: new or worse behavior and thought problems new or worse bipolar illness new psychotic symptoms (such as hearing voices, or seeing or believing things that are not real) or new manic symptoms Tell your healthcare provider about any mental problems you or your child have or about a family history of suicide, bipolar illness, or depression. Slowing of growth (height and weight) in children: Children should have their height and weight checked often during treatment with ARYNTA. ARYNTA treatment may be stopped if your child is not growing or gaining weight as expected. Circulation problems in fingers and toes (Peripheral Vasculopathy, including Raynaud’s phenomenon): Signs and symptoms may include: fingers or toes may feel numb, cool, painful fingers or toes may change color from pale, to blue, to red Tell your healthcare provider if you or your child have numbness, pain, skin color change, or sensitivity to temperature in your fingers or toes. Serotonin Syndrome: A potentially life-threatening problem called serotonin syndrome may happen when ARYNTA is taken with certain other medicines. Stop taking ARYNTA and call your healthcare provider or go to the nearest hospital emergency room right away if you or your child develop any of the following signs and symptoms of serotonin syndrome: agitation fast heartbeat seizures sweating confusion tremors, stiff muscles, or muscle twitching changes in blood pressure nausea, vomiting, diarrhea flushing coma loss of coordination dizziness seeing or hearing things that are not real (hallucination) high body temperature (hyperthermia) New or worsening tics or worsening Tourette’s syndrome: Tell your healthcare provider if you or your child get any new or worsening tics or worsening Tourette’s syndrome during treatment with ARYNTA. Before taking ARYNTA, tell your doctor about all your medical conditions, including if you or your child: Have heart problems, heart disease, heart defects, or high blood pressure, or have a family history of sudden death or heart rhythm problems Have mental problems including psychosis, mania, bipolar illness, or depression or have a family history of suicide, bipolar illness, or depression Have circulation problems in fingers and toes Have kidney problems Have or had repeated movements or sounds (tics) or Tourette’s syndrome, or have a family history of tics or Tourette’s syndrome Are pregnant or plan to become pregnant. ARYNTA may harm the unborn baby. Tell your healthcare provider if you become pregnant or think you may be pregnant during treatment with ARYNTA. Are breastfeeding or plan to breastfeed. ARYNTA passes into breast milk. You should not breastfeed during treatment with ARYNTA. Talk to your healthcare provider about the best way to feed the baby during treatment with ARYNTA. Tell your healthcare provider about all the medicines that you or your child take, including: Prescription and over-the-counter medicines, vitamins, and herbal supplements. ARYNTA can affect the way other medicines work and other medicines may affect how ARYNTA works. Taking ARYNTA with other medicines can cause serious side effects. Sometimes the doses of other medicines will need to be changed during treatment with ARYNTA. The most common side effects of ARYNTA: In children 6 to 17 years and adults with ADHD include decreased or loss of appetite, diarrhea, dry mouth, trouble sleeping, stomach pain, anxiety, weight loss, dizziness, irritability, nausea, and vomiting. In adults with BED include dry mouth, decreased appetite, constipation, anxiety, trouble sleeping, increased heart rate, and feeling restless. The Important Safety Information does not include all the information needed to use ARYNTA safely and effectively. Please see accompanying full Prescribing Information for ARYNTA. To Report SUSPECTED ADVERSE REACTIONS, contact Azurity Pharmaceuticals, Inc. at 1-800-461-7449, or FDA at 1-800-FDA-1088 or www.fda.gov/MedWatch. ARYNTATM is a trademark of Azurity Pharmaceuticals, Inc. ©2025 Azurity Pharmaceuticals, Inc. PP-ARY-US-0003 References Arynta [package insert]. Woburn, MA: Azurity Pharmaceuticals, Inc; 2025. Boellner SW, Stark JG, Krishnan S, Zhang Y. Pharmacokinetics of lisedexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study. Clin Ther. 2010;32(2):252-264 Jasinski DR, Krishnan S. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacol. 2009;23(4):419–427. Jasinski DR, Krishnan S. Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. J Psychopharmacol. 2009;23(4):410–418. Kaland ME, Klein-Schwartz W. Comparison of lisdexamfetamine and dextroamphetamine exposures reported to U.S. poison centers. Clin Toxicol (Phila). 2015;53(5):477–485. Polaha J, Dalton WT 3rd, Lancaster BM. Parental report of medication acceptance among youth: implications for everyday practice. South Med J. 2008;101(11):1106-1112. Houghton R, Ong RC, Bolognani F. Psychiatric comorbidities and use of psychotropic medications in people with autism spectrum disorder in the United States. Autism Res. 2017;10(12):2037–2047. American Academy of Child and Adolescent Psychiatry. ADHD in Youth With ASD: Parents’ Medication Guide. Published 2023. Accessed July 7, 2025. https://www.aacap.org/App_Themes/AACAP/docs/resource_centers/resources/med_guides/ADHDwithASD_Web.pdf Cermak SA, Curtin C, Bandini LG. Food selectivity and sensory sensitivity in children with autism spectrum disorders. J Am Diet Assoc. 2010;110(2):238–246. Cutler AJ, Mattingly GW. Beyond the pill: new medication delivery options for ADHD. CNS Spectr. 2017;22(6):463–474. About Azurity Azurity Pharmaceuticals is a privately held global pharmaceutical company dedicated to addressing the critical and often invisible crisis facing overlooked patients by offering innovative solutions to meet their specific, unmet needs, which often are ignored by the broader biopharmaceutical industry and not typically addressed by generic manufacturers. By reformulating, adapting, and developing new therapies that meet specialized patient needs, we are delivering treatment alternatives that solve issues impacting patients’ day-to-day lives. Azurity has a broad portfolio of more than 50 medicines across 10 therapeutic areas fueling its mission, powered by a next generation AI-driven sales and marketing tool called Azurity Commercial Excellence (ACE) to optimize customer engagement and improve product delivery to overlooked patients. For more information, visit www.azurity.com. Media Contact media@azurity.com ©2026 Azurity Pharmaceuticals, Inc. All rights Reserved. This is intended for viewership in U.S. only. This press release may contain forward-looking statements subject to risks and uncertainties; actual results may differ materially. PP-ARY-7095-US-EN-v1 04/26